Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Fletcher, 2013
2015
Schöffski, 2014, Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease, Oncol Res Treat, 37, 355, 10.1159/000362631
Mastrangelo, 2012, Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions, Cancer, 118, 5339, 10.1002/cncr.27555
Stiller, 2013, Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project, Eur J Cancer, 49, 684, 10.1016/j.ejca.2012.09.011
Nedea, 2006, Sarcoma and skin radiation oncology, Hematol Oncol Clin North Am, 20, 401, 10.1016/j.hoc.2006.01.017
Maki, 2007, Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002, J Clin Oncol, 25, 2755, 10.1200/JCO.2006.10.4117
Munhoz, 2015, A Phase Ib/II study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas, Oncologist, 20, 1245, 10.1634/theoncologist.2015-0245
Dickson, 2015, Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma, Sarcoma, 2015, 532478, 10.1155/2015/532478
García-Del-Muro, 2011, Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study, J Clin Oncol, 29, 2528, 10.1200/JCO.2010.33.6107
2014, Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii102
Dybdal-Hargreaves, 2015, Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent, Clin Cancer Res, 21, 2445, 10.1158/1078-0432.CCR-14-3252
Smith, 2010, Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability, Biochemistry, 49, 1331, 10.1021/bi901810u
Funahashi, 2014, Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci, 105, 1334, 10.1111/cas.12488
Yoshida, 2014, Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br J Cancer, 110, 1497, 10.1038/bjc.2014.80
E7389 administered as an IV bolus infusion day 1 and day 8 every 3 weeks in pre-treated patients with advanced and/or metastatic soft tissue sarcoma (NCT00413192). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00413192 (accessed July 22, 2015).
Schöffski, 2011, Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes, Lancet Oncol, 12, 1045, 10.1016/S1470-2045(11)70230-3
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
2009
Demetri, 2015, Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial, J Clin Oncol
Paz-Ares, 2012, Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone, Invest New Drugs, 30, 729, 10.1007/s10637-010-9561-9
van der Graaf, 2012, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 379, 1879, 10.1016/S0140-6736(12)60651-5
Cortes, 2011, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6
Kaufman, 2015, Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, 33, 594, 10.1200/JCO.2013.52.4892
Blay, 2015, Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 16, 531, 10.1016/S1470-2045(15)70102-6
Judson, 2014, Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial, Lancet Oncol, 15, 415, 10.1016/S1470-2045(14)70063-4